X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2022/09/14/2516211/0/en/Sermonix-Pharmaceuticals-Shares-Details-of-First-Ever-Known-Durable-Complete-Clinical-Response-in-a-Metastatic-ER-HER2-Breast-Cancer-Patient-With-an-ESR1-Mutation-After-Prior-CDK4-.html
https://www.globenewswire.com/news-release/2022/09/13/2515038/0/en/Sermonix-Pharmaceuticals-Announces-Results-of-Phase-2-Study-of-Lasofoxifene-vs-Fulvestrant-in-Postmenopausal-Women-With-Locally-Advanced-or-Metastatic-ER-HER2-Breast-Cancer-and-an-.html
https://www.finsmes.com/2021/11/sermonix-pharmaceuticals-raises-40m-in-series-a3-funding.html
http://www.globenewswire.com/news-release/2021/04/21/2214280/0/en/Sermonix-Pharmaceuticals-Project-With-Huntsman-Cancer-Institute-Researcher-to-Investigate-Potential-Effects-of-Lasofoxifene-on-ESR1-Mutations-in-Endometrial-Cancer.html
https://www.globenewswire.com/news-release/2020/12/03/2139311/0/en/Sermonix-to-Present-Poster-on-Phase-2-Study-of-Lasofoxifene-in-Combination-with-Eli-Lilly-and-Company-s-Abemaciclib-at-Virtual-San-Antonio-Breast-Cancer-Symposium-2020.html
Market Place
Share 
